Loading
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Previous close
€4.02
−€0.12 · -2.90%
Regular session · ET · Market data may be delayed.
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Day range
Current €4.02
52-week range
Current €4.02
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
11
Overpriced
Sentiment
44
Mixed
Risk
66
High Risk
Momentum
31
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Day range
Current €4.02
52-week range
Current €4.02
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.48M EUR | 9.2M EUR | 17.48M EUR | 12.18M EUR | 4.19M EUR |
| Cost of goods sold | 2.8M EUR | 3.88M EUR | −23K EUR | 995K EUR | 1.02M EUR |
| Gross profit | 1.51M EUR | 9.2M EUR | 17.5M EUR | 17.06M EUR | 4.19M EUR |
| Research and development | 83.61M EUR | 90.88M EUR | 110.01M EUR | 60.47M EUR | 48.45M EUR |
| Selling, general, and administrative | 53.89M EUR | 17.1M EUR | 15.61M EUR | 15.5M EUR | 11.52M EUR |
| Operating expenses | 137.37M EUR | 106.76M EUR | 120.19M EUR | 74.17M EUR | 56.31M EUR |
| Interest income | 2.83M EUR | 1.14M EUR | 945K EUR | 390K EUR | 57K EUR |
| Interest expense | 32.3M EUR | 12.18M EUR | 5.18M EUR | 707K EUR | 138K EUR |
| Depreciation and amortization | 2.8M EUR | 5.2M EUR | 2.6M EUR | 870K EUR | 858K EUR |
| Operating income | −130.95M EUR | −97.56M EUR | −102.71M EUR | −57.11M EUR | −52.11M EUR |
| Net income | −340.16M EUR | −184.21M EUR | −110.43M EUR | −54.27M EUR | −49.64M EUR |
Company facts updated Sep 12, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Simplify Propel Opportunities ETFSURI1.26M1.54%82.87M USD2.82%$19.21-0.36%
Harbor Health Care ETF (MEDI)MEDI140.74K0.33%42.58M USD0.80%$33.38-0.00%
ActivePassive International Equity ETFAPIE55.49K—953.79M USD0.45%$39.20+0.89%
State Street SPDR Portfolio Europe ETFSPEU33.86K0.00%722.64M USD0.07%$55.65+0.55%Simplify Propel Opportunities ETFSURIHarbor Health Care ETF (MEDI)MEDIActivePassive International Equity ETFAPIEState Street SPDR Portfolio Europe ETFSPEUAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
